About Celsee Diagnostics
Celsee Diagnostics is a Healthcare company based in Plymouth (United States) founded in 2011, and was acquired by Bio Rad in April 2020. Liquid biopsy technology for monitoring circulating tumor cells is provided. Celsee Diagnostics has raised $38.43 million across 14 funding rounds from investors including Bio Rad and Ann Arbor SPARK. The company has 18 employees. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Diversified. Its competitors include Guardant Health, GRAIL and Natera; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 2011 and based in Plymouth, United States, Celsee Diagnostics operates in the biotechnology sector. An instrument system and reagent kit are offered by the company for the separation, detection, and retrieval of circulating tumor cells from peripheral whole blood. This approach serves as an alternative to invasive biopsies, utilizing microfluidic chips to capture rare cancer cells and support downstream molecular analysis for research purposes.
- Headquarters Plymouth, United States
- Employees 18
- Stage Acquired
- SectorsHealthcare
- Website celsee.com
- Social LinkedIn X
- Acquired by Bio Rad (Apr 2020)
Funding Insights of Celsee Diagnostics
Celsee Diagnostics has successfully raised a total of $38.43M across 14 strategic funding rounds. The most recent funding activity was a Series B round of $5.11 million completed in December 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $38.43M
- Total Rounds 14
- Last Round Series B — $5.11M
- First Round $5,000
(Jul 2011)
- Investors Count 1
Latest 10 of 14 funding rounds of Celsee Diagnostics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2019 | $5.11M | Series B | – | – | – |
| Nov 2018 | $18.51M | Series B | – | – | – |
| May 2018 | $2.39M | Debt – Conventional | – | – | – |
| Oct 2017 | $7.91M | Series A | – | – | – |
| Sep 2016 | $1.5M | Series A | – | – | – |
| Sep 2015 | $1.29M | Series A | – | – | – |
| Dec 2014 | $2.25M | Series A | – | – | – |
| Oct 2014 | $2M | Unspecified | – | – | – |
| Nov 2013 | $1M | Seed | – | – | – |
| Sep 2012 | $560,000 | Seed | – | – | – |
2 investors in total: 2 institutional.
Investors in Celsee Diagnostics
Celsee Diagnostics has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Bio Rad and Ann Arbor SPARK.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| annarborusa.org | ||||
Portfolio of products and services for life science research and clinical diagnostic markets | 1952 | bio-rad.com | Hercules, United States |
Investor details for Celsee Diagnostics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Celsee Diagnostics
1 people are tracked at Celsee Diagnostics (1 in leadership); the tracked headcount is 18.
| Name | Role | Group |
|---|---|---|
Christopher Siemer | Founder | Leadership |
Complete people profiles for Celsee Diagnostics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Celsee Diagnostics
4 dated milestones of Celsee Diagnostics across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Celsee Diagnostics is founded.
- Funding First funding round of $5K.
- Funding Latest funding round, Series B, of $5.1M.
- Exit Acquired by Bio Rad.
Competitors of Celsee Diagnostics
Celsee Diagnostics has 3 listed competitors in our database, 3 of them funded. They include Guardant Health, GRAIL and Natera.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| grail.com | 2016 | Menlo Park, United States | $2B | 491 | Circulating tumor DNA is screened for early cancer detection. | |
| natera.com | 2004 | Redwood, United States | $152.1M | 3,293 | Developer of cell-free DNA testing for oncology, women’s health, and organ health |
Detailed competitors of Celsee Diagnostics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Celsee Diagnostics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Celsee Diagnostics
Complete news archive for Celsee Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Celsee Diagnostics
Celsee Diagnostics was founded in 2011.
Celsee Diagnostics is headquartered in Plymouth, United States. It is registered at Plymouth, Massachusetts, United States.
Celsee Diagnostics is a funded company, having raised a total of $38.43M across 14 funding rounds to date. The company's 1st funding round was a Seed of $560K, raised on Jul 2011.
Celsee Diagnostics has 18 employees.
Founded in 2011 and based in Plymouth, United States, Celsee Diagnostics operates in the biotechnology sector. An instrument system and reagent kit are offered by the company for the separation, detection, and retrieval of circulating tumor cells from peripheral whole blood. This approach serves as an alternative to invasive biopsies, utilizing microfluidic chips to capture rare cancer cells and support downstream molecular analysis for research purposes.
Celsee Diagnostics's top competitors include Guardant Health, GRAIL and Natera.
Celsee Diagnostics has 2 investors. Key investors include Bio Rad, and Ann Arbor SPARK.
Yes. Celsee Diagnostics was acquired by Bio Rad in April 2020.